Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy

Jorge E. Cortes, Hagop M. Kantarjian, Michael J. Mauro, Fiona An, Sonja Nick, Eric Leip, Carlo Gambacorti-Passerini, Tim H. Brümmendorf

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Long-term follow-up (≥4 years) demonstrated a low incidence of cardiac and vascular treatment-emergent adverse events (TEAEs) with bosutinib treatment. We evaluated cardiac, vascular, hypertension, and effusion TEAEs after ≥ 7 years of follow-up in patients with Philadelphia chromosome–positive (Ph+) leukemia. Methods: This retrospective analysis of a phase I/II study and its ongoing extension study included data from patients with chronic phase chronic myeloid leukemia (CML) treated with bosutinib after resistance/intolerance to imatinib (CP2L) or to imatinib plus dasatinib and/or nilotinib (CP3L), and those with accelerated/blast phase CML or acute lymphoblastic leukemia after treatment with, at a minimum, imatinib (ADV). Results: In all, 570 patients were treated with bosutinib; median treatment duration was 11.1 months (range: 0.03-133.1). The incidence of cardiac, vascular, hypertension, and effusion-related TEAEs was 10.9%, 8.8%, 9.1%, and 13.3%, respectively. Few patients had maximum grade 3-4 TEAEs (cardiac, 3.9%; vascular, 4.0%; hypertension, 3.0%; effusion, 4.6%). Grade 5 TEAEs occurred in the cardiac (0.7%) and vascular (1.8%) clusters only. In years 5-7, fewer than 5% of patients each year had newly occurring cardiac, vascular, hypertension, or effusion TEAEs. The exposure-adjusted TEAE rates (patients with TEAEs/total patient-year) pooled across CP2L, CP3L, and ADV cohorts were as follows: cardiac, 0.044; vascular, 0.035; hypertension, 0.038; and effusion, 0.056, of which, correspondingly, 0.9%, 1.2%, 0%, and 2.1% required treatment discontinuation. Conclusions: The incidence of cardiac, hypertension, vascular, and effusion events was low in patients with Ph+ CML resistant or intolerant to prior therapy who were treated with bosutinib.

Original languageEnglish (US)
JournalEuropean Journal of Haematology
DOIs
StateAccepted/In press - 2021

Keywords

  • bosutinib
  • cardiovascular events
  • chronic myeloid leukemia
  • clinical trial
  • effusion events
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy'. Together they form a unique fingerprint.

Cite this